Accessibility, Pattern of Use and Implications of Restricted Availability of Medicines for Treatment of Substance Abuse in a Tertiary Level Health Care.

Slides:



Advertisements
Similar presentations
MEDICATION ASSISTED ADDICTION TREATMENT: APPROPRIATE USE DAS Quarterly Provider Meeting Louis E. Baxter, Sr., M.D., FASAM Medical Director-DAS President.
Advertisements

NEX in treatment services 8 August The guidance Ensure services offering opioid substitution therapy also make needle and syringes available to.
Introduction to Drug Misuse Les Goldman. Objectives Gain basic knowledge of Common current patterns of drug misuse Local referral pathways Available treatments.
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Bringing Opioid Substitution Treatment to scale Dr. M. Suresh Kumar Inter-country Consultation on Preventing HIV among IDUs Scaling Up: From Evidence to.
1 Potential & Actual Opioid Diversion in Vietnam, Methods of Preventing Diversion, and Barriers to “Balance” Eric Krakauer, MD, PhD Harvard Medical School.
Swinomish Wellness Program
National AIDS Control Programme 1. National AIDS Control Programme (NACP) launched under Ministry of Health & Family Welfare in 1992 NACP I (1992 – 1999)
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
+ Opioid Substitution Therapy for Injecting Drug Users: Scale versus Quality WORKSHOP “OST in Developing Countries: A Primer” Atul Ambekar, Alok Agrawal.
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.
Basic Cost / Benefit Analysis of Drug Court Client Costs Prescription Drug Abuse and Overdose Prevention Rapid Response Drug Task Force Presented to the.
Psychopharmacotherapy in Correctional Institutions Robert P. Schwartz, M.D. Friends Research Institute Supported by NIDA R01 DA (PI: Kinlock)
Substance Abuse Treatment. PROFILE OF A DRUG ABUSER  MOST PEOPLE IN TREATMENT ARE BETWEEN YEARS OF AGE  MANY DRUG ABUSERS SUFFER FROM MENTAL HEALTH.
HIV and Injection Drug Use
F/C AETC Faculty HIV HCV Thursday, March 12, 2015 | 1:30pm EDT Medical Facilitator/Didactic Presenter Todd S. Wills, MD University of South Florida Case.
Behavioral Interventions for HIV Risk Reduction and HIV Prevention: An International Perspective Marek C. Chawarski Yale University School of Medicine.
Injecting Drug Use and Drug Led HIV in Nepal Bijay Pandey Recovering Nepal.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
PSYCHOPATHOLOGY OF CHILDREN AND FAMILY
Healthcare Reform The “Affordable Care Act” How Will It Affect Substance Abuse Care?
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
OPIOID SUBSTITUTION THERAPY
Co-occurring Challenges: Leveraging ADAP and ACA to Address Hepatitis C and Substance Use Disorders Daniel Raymond Policy Director Harm Reduction Coalition.
TI for IDUs Sexual IDUBlood Perinatal Unidentified Routes of HIV Transmission SENTINEL SURVEILLANCE 2006 HIV infection in India.
Opioid addiction treatment: Challenges (and opportunities) for community practice Marc Fishman MD.
Addiction Treatment as HIV Prevention Charles P. O’Brien, MD, PhD David Metzger, PhD George E. Woody, MD University of Pennsylvania Treatment Research.
For Pain or Not for Pain: Methadone Madness
A global perspective on scaling up harm reduction 2 nd National Harm Reduction Conference, Ukraine, March 2007 Dr Jos Perriens, Director Prevention.
Introduction About HIV/AIDS in Hangzhou Hangzhou Center For Disease Control And Prevention — by Zhao Gang — by Zhao Gang.
Arash Ghodousi Addiction Therapy 2015 Florida, USA August 03-08, 2015.
1 HIV and Injection Drug Use HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Coverage and Management of Medications for Treating Substance Abuse in Health Plans Constance M. Horgan, Sc.D. Sharon Reif, Ph.D. Dominic Hodgkin, Ph.D.
Promoting Rational Use of ARVs in HIV/AIDS Clinics in Tanzania Presented by Salama Mwakisu -MSH.
Special patient groups Module 5. Introduction Worldwide, the majority of people in substitute treatment are men between Even they do not form a.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Buprenorphine {Suboxone®, Subutex®}
Management of Substance Use Disorder Module P: Addiction-Focused Pharmacotherapy.
Methadone Maintenance System Performance Measures – 2011/2012 Office of the Provincial Health Officer January 28, Dr. Eric Young, MD, MHSc, CCFP,
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Medication Assisted Treatment Adding a new medication into outpatient treatment.
Focus on Addictions and Homelessness Catriona Ritchie NHSGGC Addictions Services GP ST 1+2 Teaching – Deprivation Related Problems in General Practice.
Buprenorphine Joseph Merrill M.D., M.P.H. University of Washington Harborview Medical Center.
After the ED Alcohol & Drug Treatment Options Dr Mark Daglish Director of Addiction Psychiatry Royal Brisbane & Women’s Hospital.
1 Use of Pharmacotherapies by Substance Abuse Treatment Facilities November 2007 Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration.
Developing role of community pharmacy in responding to the needs of people with drug problems David Thomson Lead Pharmacist Community Pharmacy Development.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Presented by Nathalie Rose Social Worker PILS (Prevention Information Lutte contre le Sida) 5 August, 2008 IAC.
Medical Assisted Treatment
Substance Exposed Newborns: Addressing Substance Use Disorder
Medication Assisted Treatment
Medication-Assisted Therapy at Coleman Profession Services
McLean Hospital Division of Alcohol and Drug Abuse
Drug Abuse Treatment as HIV Prevention: The State of the Science
Opioids – A Pharmaceutical Perspective on Prescription Drugs
Medication Assisted Treatment
Evaluation of California’s Hub and Spoke System
Maintenance Treatment
matri Medication Assisted Treatment Reentry Initiative
Comparative Effectiveness of Alcohol and Drug Treatment in HIV Infected Veterans Kevin L. Kraemer, MD, MSc Professor of Medicine and Clinical & Translational.
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
The relationship between incarceration and opioid addiction treatment
Are you sick and tired of being sick and tired?
Strategic Initiatives to Address Opioid Overdose & Addiction
Medication Assisted Treatment of Opioid Use Disorder
PSYCHOPATHOLOGY OF CHILDREN AND FAMILY
Situation analysis in Kyrgyzstan
Presentation transcript:

Accessibility, Pattern of Use and Implications of Restricted Availability of Medicines for Treatment of Substance Abuse in a Tertiary Level Health Care Center in North Eastern India Amit Chakrabarti

Introduction I  Sikkim is a province in North Eastern India  Substance abuse is more prevalent in North Eastern India  Substance abusers are a significant source of HIV  8 of the 13 sentinel sites on substance abusers are in North Eastern India Source:

Introduction II  Effective treatment is key to limiting health related consequences  Effective treatment depends on availability of options  Commonest available option is medicines  Medicines can be used for detoxification and maintenance

Objectives  Medicines used for detoxification and maintenance  Effect of maintenance on retention & relapse  Pricing of medicines  Source of medicines  Availability of medicines

Study Design  Single hospital based, retrospective, no control group  From April 2001 to September 2003  Patients for detoxification / maintenance  Alcohol & injecting opioid (IDU) abuse  Hospital records  SPSS 8.0 used for analysis

Result Summary  Alcohol abuse (26%), injecting opioid abuse (4%) AlcoholOpioid DetoxificationDiazepam (88%) Clonidine (94%) Naltrexone maintenance 18%42% Maintenance cost Rs. 280 / $ 6 / week Non-retention / Relapse 76%98%

Lessons I  No effective maintenance therapy  Reluctance of treatment provider  Oral buprenorphine not used  Methadone not available  Source – private pharmacies  No supply through National Mental Health Program (NMHP)

Lessons II  Pricing high  Patient reluctance to maintenance  Naltrexone 50 mg, 1 tab – Rs. 40 / $ 1  Only 1 manufacturer for naltrexone  Only 2 manufacturers for oral buprenorphine  Treatment not covered by insurance agencies

Implications  Education of treatment providers  Availability of effective maintenance  Availability of newer medicines  Affordability through price control  Supply through NMHP  Encourage to manufacture  Insurance recognition

Research Agenda  Pilot study with oral methadone in injecting opioid abuse  Objective: Retention and health consequences, i.e., HIV  Outcome measures: 1.Retention in program 2.Reduction in needle use 3.Seroconversion